JP2001523228A - 求核性置換エクテイナシジン類およびn−オキシドエクテイナシジン類 - Google Patents
求核性置換エクテイナシジン類およびn−オキシドエクテイナシジン類Info
- Publication number
- JP2001523228A JP2001523228A JP54414098A JP54414098A JP2001523228A JP 2001523228 A JP2001523228 A JP 2001523228A JP 54414098 A JP54414098 A JP 54414098A JP 54414098 A JP54414098 A JP 54414098A JP 2001523228 A JP2001523228 A JP 2001523228A
- Authority
- JP
- Japan
- Prior art keywords
- substantially pure
- excipient
- diluent
- medicament
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000269 nucleophilic effect Effects 0.000 title abstract description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical class NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 title description 4
- 150000001204 N-oxides Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 40
- 241000798369 Ecteinascidia turbinata Species 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims description 28
- 230000000259 anti-tumor effect Effects 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 241000124008 Mammalia Species 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 239000003085 diluting agent Substances 0.000 claims 18
- 239000003937 drug carrier Substances 0.000 claims 18
- 239000000546 pharmaceutical excipient Substances 0.000 claims 18
- 229940079593 drug Drugs 0.000 claims 9
- 238000004519 manufacturing process Methods 0.000 claims 9
- 238000011321 prophylaxis Methods 0.000 claims 9
- 230000001225 therapeutic effect Effects 0.000 claims 9
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical class C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 abstract description 10
- 239000000284 extract Substances 0.000 abstract description 6
- 230000003389 potentiating effect Effects 0.000 abstract description 3
- -1 N-oxide ecteinascidin compounds Chemical class 0.000 abstract description 2
- 230000003013 cytotoxicity Effects 0.000 abstract description 2
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 2
- 229960000977 trabectedin Drugs 0.000 abstract description 2
- 230000004071 biological effect Effects 0.000 abstract 1
- 238000004587 chromatography analysis Methods 0.000 abstract 1
- 238000013467 fragmentation Methods 0.000 description 10
- 238000006062 fragmentation reaction Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 238000005556 structure-activity relationship Methods 0.000 description 2
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000013415 human tumor xenograft model Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000238 one-dimensional nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
- A01N43/58—1,2-Diazines; Hydrogenated 1,2-diazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pest Control & Pesticides (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Agronomy & Crop Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Epoxy Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. Ecteinascidia turbinataの細胞片が存在しない、実質的に純粋なエクテ イナシジン717。 2. Ecteinascidia turbinataの細胞片が存在しない、実質的に純粋なエクテ イナシジン815。 3. Ecteinascidia turbinataの細胞片が存在しない、実質的に純粋なエクテ イナシジン814。 4. Ecteinascidia turbinataの細胞片が存在しない、実質的に純粋なエクテ イナシジン802。 5. Ecteinascidia turbinataの細胞片が存在しない、実質的に純粋なエクテ イナシジン788。 6. Ecteinascidia turbinataの細胞片が存在しない、実質的に純粋なエクテ イナシジン760。 7. Ecteinascidia turbinataの細胞片が存在しない、実質的に純粋なエクテ イナシジン858。 8. Ecteinascidia turbinataの細胞片が存在しない、実質的に純粋なエクテ イナシジン789。 9. Ecteinascidia turbinataの細胞片が存在しない、実質的に純粋なエクテ イナシジン775。 10. Et717として本明細書において呼称される実質的に純粋な化合物の 有効な抗腫瘍量および医薬的に許容出来る担体、希釈剤または賦形剤を含む、医 薬または獣医薬組成物。 11. Et815として本明細書において呼称される実質的に純粋な化合物の 有効な抗腫瘍量および医薬的に許容出来る担体、希釈剤または賦形剤を含む、医 薬または獣医薬組成物。 12. Et814として本明細書において呼称される実質的に純粋な化合物の 有効な抗腫瘍量および医薬的に許容出来る担体、希釈剤または賦形剤を含む、医 薬または獣医薬組成物。 13. Et802として本明細書において呼称される実質的に純粋な化合物の 有効な抗腫瘍量および医薬的に許容出来る担体、希釈剤または賦形剤を含む、医 薬または獣医薬組成物。 14. Et788として本明細書において呼称される実質的に純粋な化合物の 有効な抗腫瘍量および医薬的に許容出来る担体、希釈剤または賦形剤を含む、医 薬または獣医薬組成物。 15. Et760として本明細書において呼称される実質的に純粋な化合物の 有効な抗腫瘍量および医薬的に許容出来る担体、希釈剤または賦形剤を含む、医 薬または獣医薬組成物。 16. Et858として本明細書において呼称される実質的に純粋な化合物の 有効な抗腫瘍量および医薬的に許容出来る担体、希釈剤または賦形剤を含む、医 薬または獣医薬組成物。 17. Et789として本明細書において呼称される実質的に純粋な化合物の 有効な抗腫瘍量および医薬的に許容出来る担体、希釈剤または賦形剤を含む、医 薬または獣医薬組成物。 18. Et775として本明細書において呼称される実質的に純粋な化合物の 有効な抗腫瘍量および医薬的に許容出来る担体、希釈剤または賦形剤を含む、医 薬または獣医薬組成物。 19. Et717として本明細書において呼称される実質的に純粋な化合物の 有効な抗腫瘍量および医薬的に許容出来る担体、希釈剤または賦形剤の、哺乳類 の腫瘍を患っている患者の治療的または予防的処置のための医薬の製造のための 使用。 20. Et815として本明細書において呼称される実質的に純粋な化合物の 有効な抗腫瘍量および医薬的に許容出来る担体、希釈剤または賦形剤の、哺乳類 の腫瘍を患っている患者の治療的または予防的処置のための医薬の製造のための 使用。 21. Et814として本明細書において呼称される実質的に純粋な化合物の 有効な抗腫瘍量および医薬的に許容出来る担体、希釈剤または賦形剤の、哺乳類 の腫瘍を患っている患者の治療的または予防的処置のための医薬の製造のための 使 用。 22. Et802として本明細書において呼称される実質的に純粋な化合物の 有効な抗腫瘍量および医薬的に許容出来る担体、希釈剤または賦形剤の、哺乳類 の腫瘍を患っている患者の治療的または予防的処置のための医薬の製造のための 使用。 23. Et788として本明細書において呼称される実質的に純粋な化合物の 有効な抗腫瘍量および医薬的に許容出来る担体、希釈剤または賦形剤の、哺乳類 の腫瘍を患っている患者の治療的または予防的処置のための医薬の製造のための 使用。 24. Et760として本明細書において呼称される実質的に純粋な化合物の 有効な抗腫瘍量および医薬的に許容出来る担体、希釈剤または賦形剤の、哺乳類 の腫瘍を患っている患者の治療的または予防的処置のための医薬の製造のための 使用。 25. Et858として本明細書において呼称される実質的に純粋な化合物の 有効な抗腫瘍量および医薬的に許容出来る担体、希釈剤または賦形剤の、哺乳類 の腫瘍を患っている患者の治療的または予防的処置のための医薬の製造のための 使用。 26. Et789として本明細書において呼称される実質的に純粋な化合物の 有効な抗腫瘍量および医薬的に許容出来る担体、希釈剤または賦形剤の、哺乳類 の腫瘍を患っている患者の治療的または予防的処置のための医薬の製造のための 使用。 27. Et775として本明細書において呼称される実質的に純粋な化合物の 有効な抗腫瘍量および医薬的に許容出来る担体、希釈剤または賦形剤の、哺乳類 の腫瘍を患っている患者の治療的または予防的処置のための医薬の製造のための 使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4359697P | 1997-04-15 | 1997-04-15 | |
US60/043,596 | 1997-04-15 | ||
PCT/US1998/007340 WO1998046080A1 (en) | 1997-04-15 | 1998-04-14 | Nucleophile substituted ecteinascidins and n-oxide ecteinascidins |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001523228A true JP2001523228A (ja) | 2001-11-20 |
JP4382164B2 JP4382164B2 (ja) | 2009-12-09 |
Family
ID=21927969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54414098A Expired - Lifetime JP4382164B2 (ja) | 1997-04-15 | 1998-04-14 | 求核性置換エクテイナシジン類およびn−オキシドエクテイナシジン類 |
Country Status (20)
Country | Link |
---|---|
US (1) | US5985876A (ja) |
EP (2) | EP1668985B1 (ja) |
JP (1) | JP4382164B2 (ja) |
KR (1) | KR100513668B1 (ja) |
CN (1) | CN100343235C (ja) |
AT (1) | ATE420092T1 (ja) |
AU (1) | AU747303B2 (ja) |
BR (1) | BR9808588A (ja) |
CA (1) | CA2286796C (ja) |
CY (1) | CY1108958T1 (ja) |
CZ (1) | CZ298842B6 (ja) |
DE (1) | DE69840458D1 (ja) |
DK (1) | DK1668985T3 (ja) |
ES (1) | ES2321019T3 (ja) |
HU (1) | HUP0103590A3 (ja) |
IL (1) | IL132403A (ja) |
NO (1) | NO327455B1 (ja) |
PL (2) | PL197708B1 (ja) |
PT (1) | PT1668985E (ja) |
WO (1) | WO1998046080A1 (ja) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040059112A1 (en) * | 1994-02-18 | 2004-03-25 | Rinehart Kenneth L. | Ecteinascidins |
TR200003470T2 (tr) * | 1998-05-11 | 2001-06-21 | Pharama Mar, S.A. | Ecteinascidin 743 Metabolitleri |
MY164077A (en) * | 1999-05-13 | 2017-11-30 | Pharma Mar Sa | Compositions and uses of et743 for treating cancer |
AR035842A1 (es) * | 1999-05-14 | 2004-07-21 | Pharma Mar Sa | Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo |
US7919493B2 (en) * | 2000-04-12 | 2011-04-05 | Pharma Mar, S.A. | Anititumoral ecteinascidin derivatives |
DE60111845T2 (de) * | 2000-04-12 | 2006-04-27 | Pharma Mar, S.A., Tres Cantos | Ecteinaschidin derivate mit antikrebs wirkung |
US7420051B2 (en) * | 2000-05-15 | 2008-09-02 | Pharma Mar, S.A. | Synthetic process for the manufacture of an ecteinaschidin compound |
MXPA02011319A (es) | 2000-05-15 | 2003-06-06 | Pharma Mar Sa | Analogos antitumorales de ecteinascidina 743. |
JP4391083B2 (ja) * | 2000-11-06 | 2009-12-24 | ファルマ・マール・ソシエダード・アノニマ | 効果的な抗腫瘍治療 |
GB0117402D0 (en) * | 2001-07-17 | 2001-09-05 | Pharma Mar Sa | New antitumoral derivatives of et-743 |
GB0119243D0 (en) * | 2001-08-07 | 2001-10-03 | Pharma Mar Sa | Antitumoral analogs of ET-743 |
GB0202544D0 (en) * | 2002-02-04 | 2002-03-20 | Pharma Mar Sa | The synthesis of naturally occuring ecteinascidins and related compounds |
GB0312407D0 (en) * | 2003-05-29 | 2003-07-02 | Pharma Mar Sau | Treatment |
GB0324201D0 (en) * | 2003-10-15 | 2003-11-19 | Pharma Mar Sau | Improved antitumoral combinations |
DE602004016376D1 (de) * | 2003-11-13 | 2008-10-16 | Pharma Mar Sau | Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs |
WO2005049030A1 (en) * | 2003-11-14 | 2005-06-02 | Pharma Mar, S.A. | Combination therapy comprising the use of et-743 and paclitaxel for treating cancer |
GB0326486D0 (en) * | 2003-11-14 | 2003-12-17 | Pharma Mar Sau | Combination treatment |
WO2006005602A2 (en) * | 2004-07-09 | 2006-01-19 | Pharma Mar, S.A. | Use of ecteinascidin in the treatment of cancer in patients with low level of brca1 |
WO2006035244A2 (en) * | 2004-09-29 | 2006-04-06 | Pharma Mar S.A., Sociedad Unipersonal | Ecteinascidin compounds as anti -inflammatory agents |
US20090117176A1 (en) * | 2004-10-26 | 2009-05-07 | Pharma Mar, S.A. Sociedad Unipersonal | Anticancer Treatments |
RU2382647C2 (ru) | 2004-10-29 | 2010-02-27 | Фарма Мар С.А., Сосьедад Униперсональ | Композиции, содержащие эктинэсайдин и дисахарид |
GB0522082D0 (en) | 2005-10-31 | 2005-12-07 | Pharma Mar Sa | Formulations |
CA2703026A1 (en) * | 2007-10-19 | 2009-04-23 | Rafael Rosell Costa | Prognostic molecular markers for et-743 treatment |
LT2786753T (lt) | 2010-11-12 | 2019-04-10 | Pharma Mar S.A. | Derinių terapija su antinavikiniu antibiotiku |
JOP20190254A1 (ar) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4273773A (en) * | 1979-09-24 | 1981-06-16 | American Home Products Corporation | Antihypertensive tricyclic isoindole derivatives |
US5089273A (en) * | 1986-06-09 | 1992-02-18 | Board Of Trustees Of The University Of Illinois | Ecteinascidins 729, 743, 745, 759A, 759B and 770 |
DK0574857T3 (da) * | 1992-06-19 | 1998-05-04 | Hoechst Ag | Polycycliske 31668P- og 31668U-forbindelser, fremgangsmåder til deres fremstilling samt deres anvendelse som antibiotiske eller antitumorale lægemidler |
US5426108A (en) * | 1993-11-10 | 1995-06-20 | American Cyanamid Company | Antibiotic 31F508 ALPHA1, ALPHA2, BETA1 and BETA2 |
JP4443043B2 (ja) * | 1998-04-06 | 2010-03-31 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシテイ オブ イリノイ | 半合成エクテイナシジン |
-
1998
- 1998-04-10 US US09/058,499 patent/US5985876A/en not_active Expired - Fee Related
- 1998-04-14 BR BR9808588-3A patent/BR9808588A/pt not_active IP Right Cessation
- 1998-04-14 PL PL378729A patent/PL197708B1/pl not_active IP Right Cessation
- 1998-04-14 KR KR10-1999-7009489A patent/KR100513668B1/ko not_active IP Right Cessation
- 1998-04-14 HU HU0103590A patent/HUP0103590A3/hu unknown
- 1998-04-14 AU AU71114/98A patent/AU747303B2/en not_active Ceased
- 1998-04-14 EP EP06004129A patent/EP1668985B1/en not_active Expired - Lifetime
- 1998-04-14 AT AT06004129T patent/ATE420092T1/de not_active IP Right Cessation
- 1998-04-14 PL PL98338508A patent/PL338508A1/xx not_active Application Discontinuation
- 1998-04-14 CA CA002286796A patent/CA2286796C/en not_active Expired - Fee Related
- 1998-04-14 WO PCT/US1998/007340 patent/WO1998046080A1/en active IP Right Grant
- 1998-04-14 CZ CZ0367999A patent/CZ298842B6/cs not_active IP Right Cessation
- 1998-04-14 CN CNB988060760A patent/CN100343235C/zh not_active Expired - Fee Related
- 1998-04-14 IL IL13240398A patent/IL132403A/en not_active IP Right Cessation
- 1998-04-14 JP JP54414098A patent/JP4382164B2/ja not_active Expired - Lifetime
- 1998-04-14 DE DE69840458T patent/DE69840458D1/de not_active Expired - Lifetime
- 1998-04-14 DK DK06004129T patent/DK1668985T3/da active
- 1998-04-14 PT PT06004129T patent/PT1668985E/pt unknown
- 1998-04-14 EP EP98918132A patent/EP0975218A4/en not_active Ceased
- 1998-04-14 ES ES06004129T patent/ES2321019T3/es not_active Expired - Lifetime
-
1999
- 1999-10-14 NO NO19995016A patent/NO327455B1/no not_active IP Right Cessation
-
2009
- 2009-04-06 CY CY20091100396T patent/CY1108958T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CZ298842B6 (cs) | 2008-02-20 |
EP1668985B1 (en) | 2009-01-07 |
BR9808588A (pt) | 2000-05-23 |
HUP0103590A3 (en) | 2002-07-29 |
EP0975218A4 (en) | 2001-08-08 |
HUP0103590A2 (hu) | 2002-01-28 |
CN1261254A (zh) | 2000-07-26 |
EP1668985A2 (en) | 2006-06-14 |
PL338508A1 (en) | 2000-11-06 |
PT1668985E (pt) | 2009-04-09 |
CA2286796A1 (en) | 1998-10-22 |
NO327455B1 (no) | 2009-07-06 |
NO995016L (no) | 1999-12-10 |
CA2286796C (en) | 2008-08-05 |
US5985876A (en) | 1999-11-16 |
AU747303B2 (en) | 2002-05-16 |
IL132403A0 (en) | 2001-03-19 |
DE69840458D1 (de) | 2009-02-26 |
EP1668985A3 (en) | 2006-11-22 |
KR100513668B1 (ko) | 2005-09-08 |
CN100343235C (zh) | 2007-10-17 |
ATE420092T1 (de) | 2009-01-15 |
CY1108958T1 (el) | 2012-05-23 |
JP4382164B2 (ja) | 2009-12-09 |
AU7111498A (en) | 1998-11-11 |
CZ367999A3 (cs) | 2000-07-12 |
KR20010006402A (ko) | 2001-01-26 |
PL197708B1 (pl) | 2008-04-30 |
ES2321019T3 (es) | 2009-06-01 |
DK1668985T3 (da) | 2009-05-04 |
EP0975218A1 (en) | 2000-02-02 |
WO1998046080A1 (en) | 1998-10-22 |
IL132403A (en) | 2004-09-27 |
NO995016D0 (no) | 1999-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001523228A (ja) | 求核性置換エクテイナシジン類およびn−オキシドエクテイナシジン類 | |
EP0573584A1 (en) | Method of treating pulmonary inflammation | |
EP1086701B1 (en) | Simethicone containing laxative composition | |
IE911962A1 (en) | Treatment of organ transplantation rejection | |
JPH06157344A (ja) | 血管新生阻害のための医薬製剤及び血管新生阻害方法 | |
CA2189001A1 (en) | Medicinal composition as a remedy for nonsmall cell lung cancer | |
JPS61129129A (ja) | 抗腫瘍剤 | |
JP2003509426A (ja) | 新規化合物 | |
US4512996A (en) | Benzoylecgonine or benzoylnorecgonine as active agents for the treatment of rheumatoid arthritis | |
US11319273B2 (en) | Lipophilic curcumin analogs and methods of inhibiting HIV-1, treating latent HIV in the brain, and preventing HIV-mediated cognitive decline and HIV dementia | |
US4469700A (en) | Benzoylecgonine or benzoylnorecgonine as active agents for the treatment of rheumatoid arthritis | |
CN114929682B (zh) | 苯并硫代吡喃酮类化合物的盐及其制备方法和用途 | |
EP3954374A1 (en) | Pharmaceutical combination of pimozide and methotrexate and use thereof | |
KR20230061528A (ko) | 구강 건조증의 치료에 사용하기 위한 화합물 | |
US5369119A (en) | Use of imexon as an immune suppressive and pharmaceutical compositions containing imexon | |
KR20210102335A (ko) | 메이소인디고의 결정다형 및 메이소인디고의 변형된 제형 | |
EP3998256A1 (en) | Crystalline form of cxcr2 antagonist and application thereof | |
RU2063753C1 (ru) | Способ лечения экстрапирамидного синдрома при остром отравлении галоперидолом | |
CA1333771C (en) | Use of imexon as an immune suppressive and pharmaceutical compositions containing them | |
JP2799368B2 (ja) | 抗原虫剤 | |
JPH1160483A (ja) | Tnf産生阻害剤 | |
JP2002504109A (ja) | シンコニン二塩酸を含む製薬組成物 | |
CN112022869A (zh) | 野黄芩苷的医药用途 | |
Ali et al. | Effect of ethnic origin on ampicillin bioavailability in healthy Sudanese subjects. | |
JPH0753375A (ja) | 肝臓疾患治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050408 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081104 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090202 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090316 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090302 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090609 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090723 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090901 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090917 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121002 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |